Phase II Study of KRP-209

Phase II Study of KRP-209 - A Clinical Trial to Evaluate Efficacy and Safety of KRP-209 in Patients with Subjective Tinnitus -

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221608

Enrollment

400

Registered

2011-10-05

Start date

2011-10-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subjective tinnitus

Interventions

investigational material(s) Generic name etc : KRP-209 INN of investigational material : Therapeutic category code : 119 Other agents affecting central nervous system Dosage and Administration for In

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Patients with a clinical diagnosis of first onset, persistent (i.e. tinnitus should never be absent for >24 hours in a row), subjective, uni- or bilateral tinnitus. In case of bilateral tinnitus this criterion applies to both ears.

Exclusion criteria

Exclusion criteria: - Clinical diagnosis of intermittent or pulsatile tinnitus. - Patients who have tinnitus as a concomitant sympton of a middle ear disease(such as otitis media, otosclerosis, eustachian tube dysfunction, etc), fluctuant hearing impairment(such as Meniere's disease, etc), retrocochlear hearingloss(such as acoustic neuroma), arteriovenous malformation or glomus tumor.

Design outcomes

Primary

Measure	Time frame
The amount of change from 0 weeks in the point of each evaluation. - Tinnitus handicap inventory(THI), etc. -	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026